Pfizer Corporation

Other

Bright, Gene M.

Gene M Bright

Willard M Welch, Jr

Kishor A Desai

Yuhpyng Liang Chen

Thomas Francis Seeger

Bishop Wlodecki

Robert A Volkmann

Michael Aaron Brodney

James R Hauske

Vytautas J Jasys

Anabella Villalobos

Patricia A Seymour

John A Love, Iii

Teresa A Smolarek

An aminomethylpyridyloxymethyl/benzisoxazole substituted azabicyclic compound of formula I, pharmaceutical composition comprising same, and a method of treating one or more CNS or other disorders, including concurrent treatment of disorders such as schizophrenia and depression, wherein formula I is or a pharmaceutically acceptable salt or thereof, wherein Z is wherein Y is methylene; X is oxygen; n is 0; Rand Rare each hydrogen or halogen; and Rand Rtogether with the nitrogen atom to which they are attached form i) a saturated non-aromatic 3 to 7 membered monocyclic ring, said ring i) being unsubstituted or substituted or substituted with one or more (C&#x2013;C)alkyl, (C&#x2013;C)alkoxy(C&#x2013;C)alkyl, or hydroxy groups.

Pyridyloxymethyl and benzisoxazole azabicyclic derivatives

The present invention relates to compounds of Formula I,wherein R, R, R, R, and n are as defined, and to pharmaceutically acceptable salts of said compounds. Compounds of Formula I have activity in agonizing 5HT7 receptors and are useful in treating, for example, disorders that can be treated by modulating circadian rhythms.

Quinoline derivatives

A pharmaceutical composition for treating a disorder that is treated by modulation of serotonergic neurotransmission comprising administering (7S,9aS)-cis-2-Benzo[d]isoxazol-3-yl-7-(3-pyrrolidin-1-ylmethyl-phenoxymethyl)-octahydro-pyrido-[1,2-a]pyrazine and sertraline is disclosed.

Treatment of depression or generalized anxiety disorder

5HT1 antagonists for antidepressant therapy

Azabicyclic 5HT1 receptor ligands

Methods of administering CRF antagonists

Substituted pyrazoles as corticotropin-releasing factor (CRF) antagonists

The compounds of the formula wherein A, R.sub.1, R.sub.3, X.sub.1, Y and Z are as defined herein, have corticotropin-releasing factor (CRF) antagonist activity. They are useful in the treatment of illnesses induced by CRF, such as stress and anxiety related disorders.

Substituted pyrazoles as CRF antagonists

Acyclic anc cyclic amides as neurotransmitter release enhancers

Amino-substituted pyrazoles having CRF antagonistic activity

Compounds of the formula ##STR1## wherein B, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are as defined herein with reference to formula IX have corticotropin-releasing factor antagonist activity and as such are of use in the treatment of panics, phobias and other stress-related disorders.

Racemic or optically active pyrido[1,2-a]pyrazine derivatives of the formula ##STR1## wherein X is N or CH and Y represents one of certain pyrazolo, triazolo, tetrazolo or cyclic imido radicals are useful in the treatment of abuse of and/or addiction to such substances as narcotics, alcohol and nicotine.

Pyridopyrazine derivatives for treating alcohol and nicotine abuse and

Neuroleptic 2-substituted perhydro-1-h-pyrido[1,2-a]pyrazines

A series of bridged bicyclic imide compounds having a 4-(4-[2-pyrimidinyl]-1-piperazinyl)butyl group attached to the imide nitrogen are useful for alleviating the symptoms of anxiety and depression in human subjects.

Bridged bicyclic imides as anxiolytics and antidepressants

Growing community of inventors

Groton, CT, United States of America

Gene M Bright